

Clinical trials of Celacade system

TrialResults-center www.trialresultscenter.org

1 heart failure

Trial	Treatments	Patients	Trials design and methods
Celacade system vs placebo			
ACCLAIM , 2008 [NCT00111969] n=1213/1213 follow-up: 10.2 months	device-based non-specific immunomodulation therapy with Celacade system versus placebo	patients with NYHA functional class II-IV chronic heart failure, left ventricular (LV) systolic dysfunction, and hospitalisation for heart failure or intravenous drug therapy in an outpatient setting within the past 12 months.	Parallel groups double blind

More details and results :

- anti inflammatory drugs for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q312>

References

ACCLAIM, 2008:

Torre-Amione G, Anker SD, Bourge RC, Colucci WS, Greenberg BH, Hildebrandt P, Keren A, Motro M, Moy LA, Otterstad JE, Pratt CM, Ponikowski P, Rouleau JL, Sestier F, Winkelmann BR, Young JB Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet 2008;371:228-36 [[18207018](#)]